Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
Year: 1996
Type: article
Study design: Clinical Trial
Source: PubMed
Authors: N J Meropol, M Porter, L E Blumenson, M J Lindemann, R P Perez, L Vaickus, G M Loewen, P J Creaven, K A Wilkes, M A Giedlin, M A Caligiuri
Institution: Roswell Park Comprehensive Cancer Center
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: closed
Funder: National Cancer Institute
OpenAlex ID: W1908894798